# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Roundhill CEO Dave Mazza says investors "can't just buy a basket of big pharma names or a broad-based biotech ETF and c...
Nestlé SA launches Vital Pursuit, a new food line tailored for GLP-1 weight loss medication users, featuring protein, fiber, an...
- Reuters
Eli Lilly's diabetes drug tirzepatide receives approval in China, intensifying competition with Novo Nordisk's Ozempic....
Eli Lilly phase 3 trials reveal once-weekly insulin efsitora as a non-inferior alternative to daily basal insulins for type 2 d...
Efsitora met the primary endpoint in both QWINT-2 and QWINT-4 with once-a-week dosing regimen for people living with type 2 d...